Defence's arm-x anti-cancer vaccine inhibits growth of pre-established ovarian cancer resulting in complete responses in treated animals

Vancouver, british columbia--(newsfile corp. - june 25, 2024) - defence therapeutics inc. (cse: dtc) (fse: dtc) (otcqb: dtcff) ("defence" or the "company"), a canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation arm-x anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (id8 model) when combined with the anti-pd-1 immune-checkpoint inhibitor. figure 1 to view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8000/214171_cc2e2f8084a9e943_002full.jpg using defence's accum® platform, the company previously demonstrated that accutox® treatment of mscs results in the induction of antigen cross-presentation capacity (arm-x cells), which can mount potent anti-tumoral responses in animal pre-clinical models.
ARM Ratings Summary
ARM Quant Ranking